Drug Profile
Research programme: amyotrophic lateral sclerosis therapeutics - Montreal Neurological Institute/Takeda
Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Montreal Neurological Institute and Hospital; Takeda
- Class Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for research development in Amyotrophic-lateral-sclerosis in Canada
- 04 Dec 2017 Takeda and Montreal Neurological Institute agree to develop therapeutics for Amyotrophic lateral sclerosis in Canada
- 04 Dec 2017 Early research in Amyotrophic lateral sclerosis in Canada (unspecified route)